Quick Answer
eCTD Module 5 contains clinical study reports and clinical data organization. Its structure includes 5.1 table of contents, 5.2 tabular listing of all clinical studies, 5.3 clinical study reports, and 5.4 literature references. Section 5.3 includes biopharmaceutic studies, human biomaterial studies, human pharmacokinetic studies, human pharmacodynamic studies, efficacy and safety studies, postmarketing experience, and case report forms or listings where required.
Key Takeaways
- Module 5 is the clinical study report module of the CTD.
- Section 5.2 provides a tabular listing of all clinical studies.
- Section 5.3 contains the clinical study reports and related clinical evidence.
- Section 5.4 contains literature references.
- Module 5 should align with Module 2.5 Clinical Overview, Module 2.7 Clinical Summary, proposed labeling, and study datasets.
- This article focuses on eCTD Module 5 structure. For deeper clinical submission guidance, see the eCTD Module 5 clinical guide. For the complete five-module framework, see eCTD structure explained.
Why Module 5 Structure Matters
Module 5 is where reviewers find the clinical evidence behind efficacy, safety, dosing, clinical pharmacology, and proposed labeling. A submission can have strong clinical data and still create review friction if the reports, listings, summaries, datasets, and label claims do not align.
Module 5 should make it easy to answer:
- Which studies are pivotal?
- Which studies are supportive?
- Which reports support the proposed indication?
- Which reports support dose selection?
- Which safety data support warnings or precautions?
- Which clinical pharmacology evidence supports dosing, interactions, or special populations?
- Where are individual patient listings or case report forms included if required?
The structure should help reviewers move from the tabular listing to the full clinical reports and back to the clinical summaries in Module 2.
What Is eCTD Module 5?
eCTD Module 5 contains clinical study reports and related clinical documentation. It is the detailed clinical evidence layer of the CTD.
Module 2.5 and 2.7 summarize and interpret clinical evidence, but Module 5 contains the underlying reports and references.
Reviewers should be able to use Module 5 to understand:
- Which clinical studies were conducted
- How studies were designed and analyzed
- What populations were studied
- What efficacy and safety results were observed
- How clinical pharmacology supports dosing and labeling
- How clinical evidence supports the proposed indication
eCTD Module 5 Section Structure
| Section | Title | Purpose |
|---|---|---|
| 5.1 | Table of Contents of Module 5 | Navigation for Module 5 |
| 5.2 | Tabular Listing of All Clinical Studies | Overview table of clinical studies |
| 5.3 | Clinical Study Reports | Full clinical study reports and related clinical evidence |
| 5.4 | Literature References | Clinical literature references |
The structure is based on ICH M4E. It is intended to be common across regions, with region-specific administrative content kept in Module 1.
How Module 5 Connects to Module 2 and Labeling
Module 5 contains the detailed reports. Module 2.5 and 2.7 summarize and interpret those reports. Proposed labeling should reflect the same clinical evidence.
Before filing, compare:
- Study identifiers in 5.2, 5.3, and Module 2.7
- Pivotal study descriptions in the clinical overview and study reports
- Efficacy endpoints and results used in summaries and labeling
- Safety population definitions and exposure summaries
- Adverse event, serious adverse event, discontinuation, and death summaries
- Clinical pharmacology conclusions and dose recommendations
- Special population findings and labeling language
The submission should not require reviewers to decide which version of the clinical story is correct.
Section 5.2: Tabular Listing of All Clinical Studies
Section 5.2 gives reviewers a structured overview of the full clinical program.
The tabular listing should help reviewers see:
- Study identifier
- Study title
- Study design
- Study population
- Treatment arms
- Study status
- Report location
- Relationship to the proposed indication
The listing should match the reports in 5.3 and the summaries in Module 2.
Section 5.3: Clinical Study Reports
Section 5.3 contains the clinical study report structure.
| Section | Content |
|---|---|
| 5.3.1 | Reports of biopharmaceutic studies |
| 5.3.2 | Reports of studies pertinent to pharmacokinetics using human biomaterials |
| 5.3.3 | Reports of human pharmacokinetic studies |
| 5.3.4 | Reports of human pharmacodynamic studies |
| 5.3.5 | Reports of efficacy and safety studies |
| 5.3.6 | Reports of postmarketing experience |
| 5.3.7 | Case report forms and individual patient listings where required |
This structure lets reviewers move from clinical overview and summaries to the specific reports that support the indication, dosage, safety profile, and labeling.
Study Report Placement and Naming
Module 5 works best when study report placement and titles are predictable. Report names should make the study identifier and purpose clear. The tabular listing should point to the same study titles and locations used in 5.3.
Practical checks include:
- Use consistent study identifiers across 5.2, 5.3, Module 2.7, and datasets.
- Clearly distinguish pivotal, supportive, exploratory, and postmarketing evidence.
- Place clinical pharmacology studies under the relevant 5.3.1-5.3.4 sections.
- Place controlled efficacy and safety studies under 5.3.5.
- Keep literature references in 5.4 unless they are included as part of a specific report package.
- Confirm case report forms or listings are included only where required or appropriate.
This structure reduces confusion when reviewers navigate a large clinical program.
Efficacy and Safety Reports in 5.3.5
Section 5.3.5 is often the highest-value part of Module 5 for NDA and BLA review. It contains reports of controlled clinical studies and other studies relevant to efficacy and safety.
The structure should make clear:
- Which studies are pivotal
- Which studies support safety
- Which studies support dose selection
- Which studies are supportive or exploratory
- Which reports support specific labeling claims
The clinical overview in Module 2.5 should not make claims that cannot be traced to Module 5 reports.
Section 5.3.7: Case Report Forms and Listings
Section 5.3.7 is used for case report forms and individual patient data listings where required by FDA or the application context.
This section should be controlled carefully because it can be large and sensitive. Teams should confirm current FDA expectations for what is needed in the application and how clinical datasets, listings, and reviewer guides are submitted.
Module 5 Readiness Checklist
Before filing, confirm:
- Section 5.2 lists all clinical studies accurately.
- Study identifiers match reports, datasets, Module 2 summaries, and labeling references.
- Pivotal and supportive studies are clearly identified.
- Clinical study reports are final and complete.
- Clinical pharmacology, efficacy, safety, and postmarketing reports are in the correct subsections.
- Case report forms and listings are included where required.
- Literature references are separated from study reports.
- Module 2.5 and 2.7 conclusions match the clinical reports.
- Proposed labeling does not make claims unsupported by Module 5 evidence.
This checklist should be run after final report and labeling updates, because late clinical or labeling edits can create inconsistencies.
Datasets, Listings, and Reviewer Guides
Module 5 structure also needs to align with submitted datasets, listings, and reviewer guides where applicable. Clinical study reports, tables, dataset metadata, and reviewer navigation should tell the same story.
Check that:
- Study identifiers match across reports, datasets, and reviewer guides.
- Analysis populations are described consistently.
- Efficacy and safety endpoints match the clinical summary.
- Dataset locations are clear to reviewers.
- Important listings or case report forms are included when required.
- Labeling statements can be traced to the relevant clinical evidence.
These checks reduce avoidable review friction when clinical reviewers move from the narrative report to the data package.
Common Module 5 Structure Errors
| Error | Why It Matters |
|---|---|
| Study listing does not match submitted reports | Reviewers may question completeness |
| Pivotal and supportive studies are not clearly distinguishable | Clinical review efficiency suffers |
| Module 2.7 summary differs from clinical study reports | Creates data consistency concerns |
| Labeling claim lacks traceable Module 5 support | Labeling negotiations can become difficult |
| Literature references are mixed with study reports | Navigation becomes unclear |
| Clinical datasets and report references are inconsistent | Study review can be delayed |
Module 5 structure should make the clinical evidence traceable from study listing to report to summary to labeling.
How Assyro Supports Module 5 Readiness
Assyro helps teams compare Module 5 clinical reports against Module 2.5, Module 2.7, proposed labeling, study references, and submission metadata. eCTD Validation, eCTD Authoring, and Regulatory Gap Analysis can help identify missing reports, inconsistent study identifiers, unsupported labeling claims, and cross-reference problems before submission.
For Module 5, the value is clinical traceability: every clinical conclusion should map cleanly to the right report, dataset, summary, and label claim.
eCTD Module 5 contains clinical study reports, the tabular listing of clinical studies, and clinical literature references.
References
This guide reflects FDA and ICH eCTD structure information current as of May 2026. Confirm current ICH M4E guidance, FDA submission standards, study data expectations, and application-specific requirements before filing.
About the author
Assyro Team
Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.
See Assyro in action
Catch eCTD and eSTAR errors before your FDA review cycle.
Book a 20-minute demo this week. We'll validate a sample of your submission live and show you exactly where Assyro catches what your current QC misses.